

Remarks

Claims 20 and 23 are pending in the present application. Claim 20 has been rejected under 35 U.S.C. 102(e) as anticipated by Szarek (US 6,562,836). Claims 20 and 23 have been rejected under 35 U.S.C. 102(b) as anticipated by Scolnick (WO 99/66929). Applicants respectfully request that the indicated amendments to these claims be entered for consideration. Support for the amendments may be found in the claims as originally filed.

Claim Rejections – 35 USC §102(e)

Claim 20 has been rejected under 35 U.S.C. 102(e) as anticipated by Szarek, which discloses a method for inhibiting amyloid deposits. Claim 20 has been amended to remove the reference to serine phosphoric acids.

Claim Rejections – 35 USC §102(b)

Claims 20 and 23 have been rejected under 35 U.S.C. 102(b) as anticipated by Scolnick, which discloses a method for lowering elevated blood cholesterol with a combination of an HMG-CoA reductase inhibitor and a geranylgeraniol compound. Claims 20 and 23 have been amended to remove the reference to fatty alcohol phosphates.

Respectfully submitted,



Donna Russell, Ph.D., J.D.
Attorney for Applicants
Registration No. 46,252
Customer No. 41546

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail addressed to Commissioner for Patents, USPTO, P.O. Box 1450, Alexandria, VA 22313-1450 on June 4, 2009.

